Journal of Dermatology Research and Skin Care

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Perspective - Journal of Dermatology Research and Skin Care (2023) Volume 7, Issue 6

A commentary note on immunotherapy and skin cancer prevention.

Lynn Mary*

Department of Dermatology, Massachusetts General Hospital, Bartlett Hall, 15 Parkman Street, Boston, United States

*Corresponding Author:
Lynn Mary
Department of Dermatology
Massachusetts General Hospital, Bartlett Hall, 15 Parkman Street
Boston, United

Received:25-Nov-2023,Manuscript No. AADRSC- 23-122498; Editor assigned: 27-Nov-2023, PreQC No. AADRSC- 23-122498 (PQ); Reviewed:11-Dec-2023, QC No. AADRSC- 23-122498; Revised:16-Dec-2023, Manuscript No. AADRSC- 23-122498 (R); Published:23 -Dec-2023, DOI: 10.35841/aadrsc- 7.5.181

Citation: Mary L. A short note on role of sunscreen in skin cancer prevention. Dermatol Res Skin Care. 2023; 7(6):181

Visit for more related articles at Journal of Dermatology Research and Skin Care


Skin cancer is a prevalent and potentially deadly disease that arises from the abnormal growth of skin cells, primarily caused by exposure to ultraviolet (UV) radiation from the sun or other artificial sources. While prevention strategies like sun protection and regular skin examinations are essential, recent advances in medical science have introduced a promising avenue for skin cancer prevention and treatment known as immunotherapy. Immunotherapy, also called biologic therapy, is a revolutionary approach that utilizes the body's own immune system to combat cancer cells. In the context of skin cancer, immunotherapy has shown remarkable efficacy in both preventing the development of cancer and treating existing malignancies. This article explores the principles of immunotherapy, its applications in skin cancer prevention, and the promising advancements in this field [1].


Traditionally, cancer treatments have focused on surgery, chemotherapy, and radiation therapy, which target and eliminate cancer cells but often damage healthy cells in the process. Immunotherapy, on the other hand, takes a fundamentally different approach by enhancing the body's natural defenses to identify and destroy cancer cells more effectively. The immune system comprises a complex network of cells, tissues, and organs working together to protect the body from harmful invaders, such as viruses, bacteria, and abnormal cells like cancer [2].

However, cancer cells can sometimes evade detection by the immune system or suppress its activity, allowing them to grow and spread. Immunotherapy comes in various forms, including checkpoint inhibitors, monoclonal antibodies, cancer vaccines, and adoptive cell transfer. Each of these approaches aims to stimulate the immune system to recognize and eliminate cancer cells, ultimately enhancing the body's ability to fight cancer on its own [3].

Checkpoint inhibitors

One of the most widely used forms of immunotherapy for skin cancer is checkpoint inhibitors. Checkpoints are proteins on immune cells that need to be activated to initiate an immune response. However, cancer cells can exploit these checkpoints to evade detection by the immune system. Checkpoint inhibitors block these proteins, allowing the immune system to recognize and attack cancer cells. In the context of skin cancer, checkpoint inhibitors such as pembrolizumab and nivolumab have shown remarkable success in treating advanced melanoma, the deadliest form of skin cancer. These drugs have been approved by regulatory agencies for use in metastatic melanoma and have demonstrated prolonged survival rates and durable responses in patients [4].

Monoclonal antibodies

Monoclonal antibodies are laboratory-produced molecules that can mimic the immune system's ability to fight off harmful pathogens and cancer cells. In skin cancer, monoclonal antibodies can be designed to target specific proteins on the surface of cancer cells, hindering their growth and promoting their destruction by the immune system. For example, the monoclonal antibody ipilimumab targets a protein called CTLA-4, which plays a role in inhibiting the immune response. By blocking CTLA-4, ipilimumab enhances the immune system's ability to recognize and destroy melanoma cells [5].

Cancer vaccines

Cancer vaccines are another promising avenue for immunotherapy in skin cancer prevention. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells. These vaccines can be preventive or therapeutic, with the potential to prevent the development of cancer or treat existing tumors. The FDA has approved a cancer vaccine called Imiquimod for the treatment of superficial basal cell carcinoma. Imiquimod stimulates the immune system and is applied topically to the skin. While not a traditional vaccine, it exemplifies the diverse approaches within the realm of immunotherapy for skin cancer [6].

Adoptive cell transfer

Adoptive cell transfer is a more personalized form of immunotherapy that involves collecting and enhancing a patient's own immune cells before reintroducing them into the body to target cancer cells. One specific approach, called T-cell therapy, has shown promising results in various cancers, including skin cancer. In T-cell therapy, immune cells called T cells are extracted from the patient, genetically modified or enhanced to better recognize and attack cancer cells, and then infused back into the patient. This approach has demonstrated Dermatol Res Skin Care 2023 Volume 7 Issue 6 2 Citation: Mary L. A short note on role of sunscreen in skin cancer prevention. Dermatol Res Skin Care. 2023; 7(6):181 success in treating advanced melanoma and holds great potential for the future of skin cancer treatment [7].

Immunotherapy in skin cancer prevention

While immunotherapy has shown significant success in treating advanced skin cancer, its role in prevention is an area of active research. Several studies and clinical trials are exploring the use of immunotherapy as a preventive strategy for individuals at high risk of developing skin cancer, such as those with a history of multiple skin cancers or certain genetic predispositions. One notable example is the development of therapeutic vaccines designed to stimulate the immune system to recognize and eliminate precancerous cells before they progress to full-blown cancer. These vaccines aim to train the immune system to identify and destroy abnormal cells early in the process, potentially preventing the development of skin cancer altogether. Additionally, on-going research is investigating the use of checkpoint inhibitors as a preventive measure for individuals with a high risk of skin cancer. By blocking the mechanisms that cancer cells use to evade the immune system, these inhibitors could enhance the body's natural defenses and reduce the likelihood of cancer development [8].

Combination therapies

Medical research is continuously evolving, and new treatments for atopic dermatitis are under development. Some emerging therapies show promise in providing additional options for those with severe or treatment-resistant eczema.


As researchers delve deeper into the potential of immunotherapy for skin cancer prevention, combination therapies are emerging as a promising approach. Combining different forms of immunotherapy or integrating immunotherapy with traditional treatments like surgery or radiation therapy may offer synergistic effects, providing a more comprehensive and effective strategy against skin cancer. Moreover, combining immunotherapy with other preventive measures, such as regular skin screenings and sun protection strategies, could enhance overall skin cancer prevention efforts. This integrated approach addresses multiple aspects of skin cancer development, from early detection to harnessing the immune system's power to eliminate abnormal cells [9].

Challenges and future directions

While immunotherapy holds immense promise in the realm of skin cancer prevention and treatment, several challenges and areas of improvement remain. One significant challenge is the identification of biomarkers that can predict a patient's response to immunotherapy. Not all patients respond equally to these treatments, and understanding the factors influencing response rates is crucial for optimizing treatment outcomes. Another challenge is the potential for immune-related adverse events, where the enhanced immune response can attack normal, healthy tissues. Striking the right balance between a robust immune response against cancer cells and minimizing harm to healthy cells is a delicate task that requires ongoing research and refinement of immunotherapy protocols. Looking ahead, the future of immunotherapy in skin cancer prevention may involve a more personalized and tailored approach. Advances in precision medicine, including the identification of specific genetic and molecular characteristics of individual tumors, could enable the development of targeted immunotherapies that address the unique features of each patient's cancer [10].


Immunotherapy represents a ground-breaking paradigm shift in the field of cancer prevention and treatment, offering new hope for individuals affected by skin cancer. While traditional methods of prevention, such as sun protection and regular screenings, remain crucial, immunotherapy adds a powerful weapon to the arsenal against skin cancer. The on going research and development in immunotherapy for skin cancer prevention highlight the dynamic nature of medical science and the commitment to finding innovative solutions to complex health challenges. As the field continues to evolve, the integration of immunotherapy into comprehensive skin cancer prevention strategies holds the potential to transform outcomes for patients at risk of or diagnosed with skin cancer. With continued advancements, immunotherapy is poised to play a central role in the future landscape of skin cancer prevention and treatment.


  1. Eigentler TK, Leiter U, Häfner HM, et al.Survival of patients with cutaneous squamous cell carcinoma: Results of a prospective cohort study.J Invest Dermatol. 2017;137(11):2309-15.
  2. Indexed at, Google Scholar, Cross Ref

  3. Nehal KS, Bichakjian CK.Update on keratinocyte carcinomas.N Engl J Med. 2018;379(4):363-74.
  4. Indexed at, Google Scholar, Cross Ref

  5. Burton KA, Ashack KA, Khachemoune A.Cutaneous squamous cell carcinoma: A review of high-risk and metastatic disease.Am J Clin Dermatol. 2016;17:491-508.
  6. Indexed at, Google Scholar, Cross Ref

  7. Cohen JL.Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer.J Clin Aesthet Dermatol. 2010;3(6):39.
  8. Indexed at, Google Scholar

  9. Werner RN, Sammain A, Erdmann R, et al.The natural history of actinic keratosis: A systematic review.Br J Dermatol. 2013;169(3):502-18.
  10. Indexed at, Google Scholar, Cross Ref

  11. Ceilley RI, Jorizzo JL.Current issues in the management of actinic keratosis.J Am Acad Dermatol. 2013;68(1):S28-38.
  12. Indexed at, Google Scholar,Cross Ref

  13. Sotiriou E, Apalla Z, Vrani F, et al.Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes: A randomized intraindividual comparison study.J Eur Acad Dermatol Venereol. 2015;29(2):325-9.
  14. Indexed at, Google Scholar,Cross Ref

  15. Pearce DJ, Camacho F, Balkrishnan R, et al.Trends in on and off?label calcipotriene use.J Dermatolog Treat. 2006;17(5):308-13.
  16. Indexed at, Google Scholar, Cross Ref

  17. Sato?Deguchi E, Imafuku S, Chou B, et al.Topical vitamin D3 analogues induce thymic stromal lymphopoietin and cathelicidin in psoriatic skin lesions.Br J Dermatol. 2012;167(1):77-84.
  18. Indexed at, Google Scholar, Cross Ref

  19. Rougier A, Dupuis D, Lotte C, et al.Regional variation in percutaneous absorption in man: Measurement by the stripping method.Arch Dermatol Res. 1986;278:465-9.
  20. Indexed at, Google Scholar, Cross Ref

Get the App